Department of Cardiology, Manipal College of Medical Sciences, Pokhara, Nepal.
Department of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Nepal.
J Nepal Health Res Counc. 2021 Dec 15;19(3):618-621. doi: 10.33314/jnhrc.v19i3.3583.
Hypertension is the most common cardiovascular disease. In Nepal, 27.3% populations are suffering from hypertension. Amlodipine is the most frequently prescribed anti-hypertensive drug. Up to 15% of patients develop pedal edema with amlodipine that may lead to discontinuation. Cilnidipine, a new calcium channel blocker, found equally effective and edema is uncommon in different studies from India. We aimed to study anti-hypertensive effect and to assess resolution of amlodipine induced Pedal edema with clinidipine.
This was a prospective, single centre observational study. Study was conducted in the department of cardiology, Manipal teaching hospital from 7th May to 6th November 2020. Hypertensive Patients who were on amlodipine for at least 6 months and presented with pedal edema were enrolled for the study.
Total of 107 patients were enrolled for the study. The mean age of patients was 56.35 ± 12.84 years, ranged from 29 to 85 years and more than half(52.3 %) were male. Of the 107 patients, 90 (84.1%) patients received 10mg of clinidipine. On follow up, all patients except three (2.8%) had resolution of pedal edema. The blood pressure reduction with clinidipine was comparable with amlodipine (p: >0.05). Three patients who had persistent edema on follow up were on higher dose of clinidipine.
The newer L and N type CCB, Clinidipine has comparable efficacy with amlodipine and well tolerated in our population. Though the incidence of pedal edema is low but can occur with clinidipine especially with higher doses.
高血压是最常见的心血管疾病。在尼泊尔,27.3%的人口患有高血压。氨氯地平是最常开的降压药。高达 15%的患者在使用氨氯地平时会出现足踝水肿,这可能导致停药。西尼地平是一种新型的钙通道阻滞剂,在印度的不同研究中发现其同样有效且水肿不常见。我们旨在研究其降压效果,并评估西尼地平是否能缓解氨氯地平引起的足踝水肿。
这是一项前瞻性、单中心观察性研究。该研究于 2020 年 5 月 7 日至 11 月 6 日在曼尼帕尔教学医院心内科进行。研究纳入了至少服用氨氯地平 6 个月且出现足踝水肿的高血压患者。
共有 107 例患者入组研究。患者的平均年龄为 56.35±12.84 岁,年龄范围为 29 至 85 岁,其中超过一半(52.3%)为男性。在 107 例患者中,90 例(84.1%)患者接受了 10mg 西尼地平治疗。随访时,除 3 例(2.8%)患者外,所有患者的足踝水肿均已消退。西尼地平的降压效果与氨氯地平相当(p:>0.05)。在随访时仍存在水肿的 3 例患者接受了更高剂量的西尼地平治疗。
新型 L 和 N 型钙通道阻滞剂西尼地平在我们的人群中与氨氯地平具有相当的疗效,且耐受性良好。虽然足踝水肿的发生率较低,但在使用西尼地平时可能会发生,尤其是在使用较高剂量时。